Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial

NCT03387917 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03387917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03387917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1
Overall status
Terminated
Start date
November 12, 2018
Completion date
December 22, 2023
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors